FY2016 EPS Estimates for Alnylam Pharmaceuticals Inc. Lifted by Analyst (ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) – Analysts at FBR & Co boosted their FY2016 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Thursday. FBR & Co analyst C. James now expects that the firm will post earnings per share of ($3.82) for the year, up from their prior forecast of ($4.11). FBR & Co has a “Outperform” rating and a $100.00 price target on the stock. FBR & Co also issued estimates for Alnylam Pharmaceuticals’ Q4 2016 earnings at ($0.48) EPS, FY2017 earnings at ($3.13) EPS, FY2018 earnings at ($2.73) EPS, FY2019 earnings at ($0.34) EPS and FY2020 earnings at $4.45 EPS.
A number of other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. cut shares of Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $83.00 to $51.00 in a research note on Thursday. Jefferies Group lowered their price target on shares of Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research report on Thursday. Credit Suisse Group AG set a $145.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, September 30th. Chardan Capital boosted their price target on shares of Alnylam Pharmaceuticals from $77.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 25th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.88.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Monday. Alnylam Pharmaceuticals has a 12 month low of $33.16 and a 12 month high of $110.75. The firm has a 50-day moving average of $70.69 and a 200-day moving average of $66.05. The firm’s market cap is $2.94 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/fy2016-eps-estimates-for-alnylam-pharmaceuticals-inc-lifted-by-analyst-alny.html
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the business posted ($0.85) earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis.
Several large investors have recently made changes to their positions in the stock. Dodge & Cox acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $139,650,000. Wellington Management Group LLP boosted its stake in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares during the period. Bridger Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $50,041,000. Slate Path Capital LP boosted its stake in shares of Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares during the period. Finally, Deerfield Management Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $18,645,000. 85.96% of the stock is owned by institutional investors.
In other news, CEO John Maraganore sold 30,151 shares of the stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.00% of the stock is currently owned by insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.